MEI Pharma Inc
Company Profile
Business description
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Contact
11455 El Camino Real
Suite 250
San Diego CA 92130
USAT: +1 858 369-7100
E: investor@meipharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
46
Stocks News & Analysis
stocks
Morningstar recommends investors reject takeover offer on A-REIT
stocks
The lessons behind the best performing stock over the last 80 years
stocks
I ignored Buffett's advice and it cost me
Morningstar Investment Ideas
Stocks
ETFs
- Australian ETFs
- Active Australian Equity ETFs
- Passive Australian Equity ETFs
- Emerging Market Equity ETFs
- Sustainable ETFs
- Active Global Equity ETFs
- Passive Global Equity ETFs
- Active Australian Fixed Interest ETFs
- Passive Australian Fixed Interest ETFs
- Active Australian Listed Property ETFs
- Passive Australian Listed Property ETFs
- Active Global Fixed Interest ETFs
- Passive Global Fixed Interest ETFs
- Active Global Infrastructure ETFs
- Passive Global Infrastructure ETFs
- Active Global Property ETFs
- Passive Global Property ETFs
Funds
- Active Australian Equity Funds
- Passive Australian Equity Funds
- Active Global Equity Funds
- Passive Global Equity Funds
- Sustainable Funds
- Emerging Market Equity Funds
- Passive Australian Listed Property Funds
- Active Australian Listed Property Funds
- Passive Global Infrastructure Funds
- Active Global Infrastructure Funds
- Active Global Property Funds
- Passive Global Property Funds
- Active Australian Fixed Interest Funds
- Passive Australian Fixed Interest Funds
- Active Global Fixed Interest Funds
- Passive Global Fixed Interest Funds
Markets
Index
|
Last price
|
Change
|
% Change
|
|---|---|---|---|
| All Ordinaries | 8,217.00 | 25.10 | 0.31% |
| CAC 40 | 7,425.26 | 72.96 | 0.99% |
| DAX 40 | 18,443.56 | 141.66 | 0.77% |
| Dow JONES (US) | 40,829.59 | 484.18 | 1.20% |
| FTSE 100 | 8,270.84 | 89.37 | 1.09% |
| HKSE | 17,277.49 | 80.53 | 0.47% |
| NASDAQ | 16,884.60 | 193.77 | 1.16% |
| Nikkei 225 | 36,159.16 | 56.59 | -0.16% |
| NZX 50 Index | 12,632.82 | 11.20 | 0.09% |
| S&P 500 | 5,471.05 | 62.63 | 1.16% |
| S&P/ASX 200 | 8,011.90 | 23.80 | 0.30% |
| SSE Composite Index | 2,744.20 | 7.72 | 0.28% |
Market Movers
Name
|
Last price
|
Change
|
% Change
|
|---|---|---|---|
| Bowen Coking Coal Ltd BCB | 0.01 | 0.00 | -22.22% |
| Red 5 Ltd RED | 0.29 | 0.01 | -1.72% |
| Pilbara Minerals Ltd PLS | 2.36 | 0.05 | -2.07% |
| Telstra Group Ltd TLS | 3.95 | 0.03 | 0.77% |
| GPT Group GPT | 5.09 | 0.01 | -0.20% |
| Steadfast Group Ltd SDF | 5.32 | 0.64 | -10.74% |
| South32 Ltd S32 | 2.99 | 0.02 | 0.67% |
| Appen Ltd APX | 1.34 | 0.10 | 7.63% |
| Core Lithium Ltd CXO | 0.09 | 0.00 | 4.76% |
| Scentre Group SCG | 3.54 | 0.01 | -0.28% |